Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2018

Aug 31, 2018

30718_dirs_2018-08-31_9db6bd51-9b00-4a92-b4bd-7edbfb52c4e0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2018-08-18

Reporting Person: Kummeth Charles R. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-08-18 Common Stock F 1338.00 $180.50 Disposed 92176.00 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Restricted Stock Units $ Common Stock (24979.00) 24979.00 Direct
Restricted Stock Units $ Common Stock (21291.00) 21291.00 Direct
Restricted Stock Units $ Common Stock (16918.00) 16918.00 Direct
Stock Option (Right to Buy) $108.49 2022-08-07 Common Stock (79517.00) 79517.00 Direct
Stock Option (Right to Buy) $106.59 2023-08-18 Common Stock (102779.00) 102779.00 Direct
Stock Option (Right to Buy) $106.59 2023-08-18 Common Stock (154169.00) 154169.00 Direct
Stock Option (Right to Buy) $86.25 2021-04-01 Common Stock (46316.00) 46316.00 Direct
Stock Option (Right to Buy) $67.46 2020-04-01 Common Stock (65000.00) 65000.00 Direct
Stock Option (Right to Buy) $67.46 2020-04-01 Common Stock (50000.00) 50000.00 Direct
Stock Options (Right to buy) $177.32 2025-08-08 Common Stock (60222.00) 60222.00 Direct
Stock Options (Right to buy) $177.32 2025-08-08 Common Stock (90334.00) 90334.00 Direct
Stock Options (Right to buy) $125.05 2024-08-09 Common Stock (117342.00) 117342.00 Direct
Stock Options (Right to buy) $125.05 2024-08-09 Common Stock (78228.00) 78228.00 Direct
Stock Options (Right to buy) $94.35 2021-08-12 Common Stock (66849.00) 66849.00 Direct

Footnotes

F1: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021.

F10: Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021

F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F3: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F4: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F5: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Vests 19,879 shares on each of 8/7/16, 8/7/17 and 8/7/18 and 19,880 shares on 8/7/19.

F7: Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.

F8: Fully exercisable

F9: Vests 15,056 shares each on 8/8/2019, 8/8/202 and 15,055 shares each on 8/8/2021, 8/8/2022